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Mesothelial-to-mesenchymal transition (MMT) is an autoregulated physiological process of tissue repair that in uncontrolled con-
ditions, such as peritoneal dialysis (PD), can lead to peritoneal fibrosis.Themaximum expression of sclerotic peritoneal syndromes
(SPS) is the encapsulating peritoneal sclerosis (EPS) for which no specific treatment exists. The SPS includes a wide range of
peritoneal fibrosis that appears progressively and is considered as a reversible process, while EPS does not. EPS is a serious
complication of PD characterized by a progressive intra-abdominal inflammatory process that results in bridles and severe fibrous
tissue formation which cover and constrict the viscera. Recent studies show that transdifferentiated mesothelial cells isolated from
the PD effluent correlate very well with the clinical events such as the number of hemoperitoneum and peritonitis, as well as with
PD function (lower ultrafiltration and high Cr-MTC). In addition, in peritoneal biopsies from PD patients, the MMT correlates
very well with anatomical changes (fibrosis and angiogenesis). However, the pathway to reach EPS from SPS has not been fully and
completely established. Herein, we present important evidence pointing to the MMT that is present in the initial peritoneal fibrosis
stages and it is perpetual over time, with at least theoretical possibility that MMT initiated the fibrosing process to reach EPS.
1. Introduction
Peritoneal dialysis (PD) is a form of renal replacement ther-
apy that uses the peritoneal membrane (PM) as semiper-
meable barrier for the exchange of toxic substances and
water. This technique has increased during the last years, in
parallel to its complications. Currently, prolonged survival
on PD has been reached due to technological advances,
prevention, and early diagnosis of uremic complications.The
basic objective of DP is the long-term preservation of the
PM function. The PM is lined by a monolayer of MCs that
have characteristics of epithelial cells and act as a permeability
barrier across which ultrafiltration and diffusion take place.
The long-term exposure to hyperosmotic, hyperglycaemic,
and low pH of dialysis solutions and repeated episodes of
peritonitis or hemoperitoneum cause injury of the peri-
toneum, which progressively becomes denuded of MCs and
undergoes fibrosis andneovascularization [1]. Such structural
alterations are considered the major cause of ultrafiltration
failure [1, 2]. In this context, it has been proposed that local
production of vascular endothelial growth factor (VEGF),
a potent proangiogenic cytokine, during PD plays a central
role in processes leading to peritoneal angiogenesis and
functional decline [2–5]. Recently, it has recognized the
role of transdifferentiation of mesothelial cells (MMT) in
peritoneal fibrosis, angiogenesis, lymphangiogenesis, and PM
2 International Journal of Nephrology
failure. The process is governed by the transforming growth
factor-𝛽 (TGF-𝛽) and the representative cell form is the
myofibroblast. TGF-𝛽 synthesis may be stimulated by glu-
cose, and infections, via peritoneal leucocyte-derived factors
and it is considered the master molecule of tissue fibrosis
[6, 7]. The maximum expression of peritoneal fibrosis or
sclerotic peritoneal syndromes (SPS) induced by PD fluids is
the encapsulating peritoneal sclerosis (EPS)which is a serious
complication of PD [8, 9].The SPS is traditionally considered
as a reversible process, while EPS is not. Emerging evidences
have indicated that MMT is persistently present in initial
and end stages of peritoneal fibrosis [10–12]. Moreover, its
significant blockade decreases the peritoneal damage induced
by PD fluids, including fibrosis and angiogenesis [13, 14].
These findings suggest that there is a chain between MMT
and SPS. But the jump from SPS to EPS has not yet been fully
established. Here we review current data regarding a possible
connection between MMT, SPS, and EPS, considering the
MMT as a new process in PD presumably involved in the
deterioration phases of PM.
2. The Peritoneal Membrane Fibrosis in PD
Peritoneal fibrosis (or sclerosis) is a term that comprises a
wide spectrum of peritoneal structural alterations, ranging
from mild inflammation to severe sclerosing peritonitis and
its most complicated manifestation, encapsulating peritonitis
sclerosis (EPS) [8, 9, 15]. Simple sclerosis (SS), an intermedi-
ate stage of peritoneal fibrosis, is themost commonperitoneal
lesion found in the patients after fewmonths on PD and could
represent the initial phase of sclerosing peritonitis syndrome
(SPS). Rubin et al. [16] described a normal thickness of the
peritoneum of 20𝜇m, which after a few months on PD could
reach up to 40 𝜇m (SS).The SPS is a progressive sclerosis that
is characterized by a dramatic thickening of the peritoneum
(up to 4000 𝜇m) and is accompanied by inflammatory
infiltrates, calcification, neovascularization, and dilatation of
blood and lymphatic vessels, being the most thickening com-
monly used pathological criterion for differential diagnosis
[17–19]. In some instances, granulated tissue is observed to
immerse in exudates containing fibrin and giant cells, proba-
bly reflecting chronic inflammation. Peritoneal fibrosis con-
sists in the accumulation of ECM proteins (collagen I, III, V,
VI, fibronectin, tenascin) in the interstitium, with augmented
number of fibroblasts, some of them with myofibroblastic
features, and mononuclear cell infiltration. In the basement
membrane there is usually accumulation of collagen IV and
laminin and proteoglycans, and polysaccharides and glyco-
proteins are also present extracellularly [8, 9, 15]. In 2003,
our group discovered that MCs undergoes a process of trans-
differentiation that is so-called epithelial to mesenchymal
transition (EMT) or mesothelial to mesenchymal transition
(MMT) by the negative effects of PD liquids [10].
2.1. Mesothelial-to-Mesenchymal Transition (MMT). MMT is
a complex and generally reversible process that starts with
the disruption of intercellular junctions and loss of apical-
basolateral polarity, typical of epithelial cells, which are
then transformed into fibroblast-like cells with increased
migratory, invasive, and fibrogenic features. The objective
of this process is to repair tissue wounds by promoting
the recovery of ancestor capabilities of epithelial cells. Cell
migration, production of extracellular matrix, and induction
of neoangiogenesis are the main activities [20].The process is
conducted by the transforming growth factor-𝛽 (TGF-𝛽).
2.2. TGF-𝛽 Is the Master Molecule in MMT and Peritoneal
Fibrosis Pathway. TGF-𝛽 is a growth factor implicated as the
causal agent in fibrosis of different tissues and organs [7].This
exists in tissues, generally in a latent and inactive form, bound
to the latency-associated peptide (LAP), and it is activated
through proteolytic cleavage by thrombospondin, plasmin,
cathepsin D, furin, and glycosidases when exposed to PD
solutions [21]. Its synthesis may be stimulated by glucose,
acid pH, and infections, via peritoneal leucocyte-derived
factors and its overexpression has been correlated to worse
PD outcomes [22–25].
Four different intracellular signal pathways are triggered
upon engagement of TGF-𝛽 to its receptors, being the
most important as the Smads cascade [26–30]. Clinically,
the factors involved in the stimulation of TGF-𝛽 and the
initiation of SPS include the following.
(1) Peritonitis is one of the most commonly invoked
pathogenic factors for SPS [8, 9]. Some etiological agents have
been identified including the bacteria Staphylococcus aureus,
Pseudomona sp., and Haemophilus influenza. These patho-
gens promote conversion of fibrinogen by coagulase to a
molecular form of fibrin particularly resistant to break down
by plasmin [31]. The mechanism by which peritonitis pro-
motes progression to SP may start by the denudation of the
mesothelium, which facilitates the peritoneal damage by the
bioincompatible compounds from PD solutions, increases
peritoneal permeability to glucose, and favours nonenzy-
matic glycosylation of submesothelial structural proteins and
decrease in fibrinolytic capacity. Furthermore, peritonitis is
associated with the increased intraperitoneal. Expression of
TGF-𝛽 and other cytokines and growth factors that may
accelerate the fibrotic process of the peritoneum [32].
(2) Time on PD: some authors [17–19], but not others
[8, 9], have found a relationship between months on PD and
the incidence of SPS. The main factor appears to be the
prolonged exposure to glucose from PD solution [33], which
is able to stimulate TGF-𝛽 and fibroblast growth factor (FGF)
productions by MC [22, 34]. In addition, we have observed
a correlation between the time on PD and the progression
MMT [10].
(3) Poor biocompatibility of dialysis fluids: high glu-
cose concentration, glucose degradation products (GDPs),
advanced glycation end-products (AGEs), low pH, and lac-
tate buffer in current PD solutions are all factors that have
been implicated in peritoneal fibrosis [32, 35, 36]. These
compounds have been associated to diminished production
of phospholipids by MC, impaired phagocytosis capacity of
macrophages, decreased activation of neutrophils [37] and
lymphocytes [38], and direct toxicity of fibroblasts. Although
the PD fluid components are risk factors for SP [37, 38], it
is not always possible to identify the triggering agents for
the progression of SP. Chlorhexidine and povidone iodine,
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Table 1: Implication of TGF-𝛽 in peritoneal fibrosis.
(i) Activates quiescent fibroblasts into myofibroblasts
(ii) Increases fibronectin production by fibroblast and MC
(iii) Induces the expression of connective tissue growth factor (CTGF) by MC
(iv) Stimulates the synthesis of PAI, the natural inhibitor of tPA, contributing to the generation of an antifibrinolytic environment
(v) Increases matrix synthesis and inhibits matrix degradation by decreasing the ratio MMPs/TIMPs
(vi) Induces MMT of MC
employed to sterilize PD connections and preparation of
surgeries, have been also implicated in the progression of SP
[39, 40]. The peritoneal catheter as well as bags and tubes for
dialysis are other risk factors that may cause reactive fibrosis
[9]. Low pH, GDPs, and AGEs are shown to have a great
capacity for stimulating the production of TGF-𝛽 [41].
(4) On the other hand, evidence for genetic predisposi-
tion to SPS has also been proposed. In fact the Japanese pop-
ulation in PD seems to be more prone to develop EPS [42].
Similar to other diseases, the genetic factors may predispose
certain PD patients to develop EPS. In this case, the genetic
polymorphisms of genes related to fibrosis and inflammatory
processes may get a great importance in triggering the EPS.
This is the case of single nucleotide polymorphisms (SNPs)
in the promoter region of the interleukin-6 (IL-6), which has
been related to transporter status [43]. However, there are few
studies about the polymorphisms and their association with
EPS, due to the large number of patients that are needed to do
these studies and the low frequency of this pathology. In this
regard, there is a study that associated RAGE polymorphisms
with EPS; however, due to the low number of patients studied
this relationship does not reach statistical significance [44].
There are a number of genes candidate to be stud-
ied which may have polymorphisms as toll-like receptors,
inflammatory cytokines, chemokines, and several growth
factors. Currently it is known around 2.4 million SNPs in
the human genome and it is estimated that there may be
millions more. In the future, it will be known which of these
variants may be related with the development of EPS or in
the perpetuation of SPS in EPS so that patients may have an
individualized treatment trying to prevent its development.
Table 1 summarizes the effects of TGF-𝛽 into the peri-
toneum.Wehave recently demonstrated that TGF-𝛽 is defini-
tively one of the most important molecules in the initiation
and perpetuation of peritoneal damage in PD. Experimen-
tally, we used [14] strategies to identify the leading roles of
TGF-𝛽 in peritoneal damage. First, in our mouse model we
induced PD MMT, fibrosis, and type-I PM failure injecting
daily glucose-rich PD liquid for 5 weeks. Two more groups
received the same stimulus and a cotreatment with inhibitors
of TGF-𝛽 two peptides (P17 and P144). Fibrosis, angiogen-
esis, and MMT decreased at the end of treatment also the
PM function was preserved. Second, mice were infected
with adenovirus encoding active TGF-𝛽 by intraperitoneal
injection, and animals were killed on day 4 after infection.
We reply all anatomical and functional changes induced by
PD fluids but also find evidence of local endothelial cells
(CD31+) conversion to fibroblasts, reinforcing the hypothesis
that TGF-𝛽 andMMT are keys in the damage induced by PD
liquids in PD.
2.3. From MMT to SPS. The importance of establishing a
connection between MMT, SPS, and EPS is the potential
therapeutic and preventive effect of blocking this axis. Also
emerging evidence suggests that partial or total blockage of
the MMT prevents early stages of PM fibrosis and angiogen-
esis and preserves the PM function [14]. Moreover, current
studies show that TGF-𝛽 is probably the most important
molecule in the PM failure development and so acts on
a single molecule, the TGF-𝛽, and facilitates therapeutic
approach [14, 45]. In fact we have shown that blockade of
TGF-𝛽 significantly attenuated PM failure induced by PD
fluids [14].
One of the biggest problems to establish the definitive
connection between SPS and EPS is that the EPS animal
model has not been fully and properly developed. While in
our mice PD model in 4 or more weeks reaches the typical
changes induced by PD fluids on humans, the peritoneal
fibrosis model with chlorhexidine results too much artificial
and extremely aggressive for PM. The experimental devel-
opment of an appropriate EPS model is mandatory. Possibly
the most appropriate EPS mice model would be to maintain
long term (months) in PD according to our model of SPS.
Once accepted this limitation, the current data suggest that
MMT and SPS are part of the process. We have analyzed
serially PM pieces of mice in PD at baseline, 15, and 30 days
and we found a linear correlation between time on PD, the
thickness of the PM, and the number of MCs cytokeratin
(+) and FSP-1 (+) in the submesothelial area (unpublished
data by us). This phenomenon was accompanied by local
progressive loss of themesothelialmonolayer which indicates
an important participation of theMMT in the development of
peritoneal fibrosis andMCsmigration to submesothelial area
(unpublished data by us). Using a TGF-𝛽 adenovirus model,
we found early MMT at day 4 after stimuli intraperitoneal
injection that was correlated with PM fibrosis [14]. Similar
finding was found by others [45]. Clinically, in MCs serially
isolated and cultured from PD effluents, the MMT was
present progressively over time in PD and is associated with
solute transport disorders and ultrafiltration failure [46]. In
PMbiopsies from 35 PD stable patients performed during the
first 2 years on PD, we demonstrated that the first morpho-
logical change in peritoneum that appears as a consequence
of PD is submesothelial thickening partially caused by the
MMT. This phenotype change is associated with an increase
in peritoneal solute transport independent of the number of
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Figure 1: Mechanism for MMT, SPS, and EPS induction as a single process. The PD fluids bioincompatibility induces overproduction of
TGF-𝛽 that initiates and perpetuates the MMT. MMT includes angiogenesis (VEGF), decreased in fibrinolytic capacity by decrease in tPA,
increased in extracellular matrix component production (collagen-1, fibronectin, etc.), and migration mediated by MMPs. MCs lost their
gene expression of E-cadherin, cytokeratins, and other and gain the expression of snail, slag, N-cadherin, and so forth. All of these changes
become to peritoneal fibrosis and sclerotic peritoneal syndromes (SPS) which are originally reversible. MMT increases in parallel to fibrosis
but its role in EPS pathogenesis is unknown. EPS is considered as irreversible process. ICAM, TGF-𝛽, and Ca-125 expression remains stables.
capillaries present in the tissue [11]. Reached this point the
following questions arise, could have peritoneal fibrosis with-
out MMT? or more specifically, could have MMT without
the participation of TGF-𝛽? Experimental data by us [13, 14]
and others [47] indicate that blocking MMT in different
degrees result in a significantly attenuation of structural and
functional changes of PM.Using the adenovirus (TGF-𝛽) and
our PD mice model, the double submesothelial staining for
cytokeratin (+) and FSP1 (+) was positive in approximately
37% of activated fibroblasts, indicating its epithelial origin
[14]. However, the peritoneal fibrosis is inhibited in more
than 50% indicating that direct inhibition of TGF-𝛽with anti-
TGF-𝛽 peptides inhibited other effects of this molecule as
the activation of regional fibroblasts. Promising results have
been also obtained acting on immune system [48], on AGEs
accumulation, or on renin-angiotensin system (ACE, AR-II,
Paricalcitol) [49] and BMP-7 which also modulate directly
or indirectly the TGF-𝛽 [13]. These arguments lead us to
conclude that TGF-𝛽 is a key in the initiation and possibly
perpetuation of an uncontrolledMMT,which leads to fibrosis
and SPS (Figure 1).
2.4. From SPS to EPS. The next question is as follows: at
which point the SPS becomes an irreversible process to
become EPS? The “two-hit” hypothesis explains the EPS as
the result of the PD injury. Two factors are required for the
onset of EPS: a predisposing factor, such as peritoneal dete-
rioration from persistent injury caused by peritoneal dialysis
(the first “hit”), and an initiating factor, such as inflammatory
stimuli superimposed on the chronically injured peritoneum
(the second “hit”). Peritoneal deterioration (consisting of
mesothelial denudation, interstitial fibrosis, vasculopathy,
and angiogenesis) leads to an increased tendency toward
plasma exudations that contain fibrin and coagulation fac-
tors. The fibrins in the exudates contribute to the intestinal
adhesions and formation of fibrin capsule. Inflammatory
stimuli caused by infectious peritonitis are superimposed on
the damaged peritoneum and act as an initiating factor to
trigger the onset of EPS. Inflammatory cytokines also induce
activation and proliferation of the peritoneal fibroblasts,
promoting peritoneal fibrosis and intestinal adhesions. The
relationship between the extent of the first and second “hits”
can be demonstrated. The extent of peritoneal damage (the
first “hit”) increases with the duration of peritoneal dialysis.
The onset of EPS depends on the total intensity of both
lesions: peritoneal damage and inflammatory stimuli. For the
onset of EPS, the total intensity must be greater than a given
threshold.The extent of the inflammatory stimuli (the second
“hit”) required for the onset of EPS therefore decreases as the
duration of peritoneal dialysis increases [42, 50].
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In both cases (acute and chronic peritoneal injury), the
TGF-𝛽 is activated with subsequent initiation and perpet-
uation of MMT and its deleterious effects (fibrosis, angio-
genesis, etc.). However, it is very difficult to establish the
point of no return in peritoneal lesions clinically because
patients with type-I PM failure usually recover functionality
and possibly tissue damage with rest peritoneal [51]. In
experimental animals, data about fibrosis reversibility are
not available. Unfortunately, the initial degree of PM fibrosis
has been determined in very few cases (peritoneal biopsies
not available). Finally a genetic component cannot be ruled
[43, 44].
2.5. From MMT to EPS. In both, experimental animals [14,
45] and human peritoneal biopsies from patients within 2
years in PD [11], it seems clear that MMT is an early phe-
nomenon able to determine the degree of peritoneal fibrosis
and the future of the PM. But no information about MMT in
patients with long term in PD or diagnosis of EPS is available.
It is possible that MMT may be an initial phenomenon and
few signs of it are in severe stages of fibrosis (Figure 1). How-
ever, in bridles and postsurgical adhesions, we have found
MMT signs (unpublished data by us), and Bowel adherences
may represent an intermediate degree between the SPS and
EPS (our unpublished data by us), which encourages to
conduct studies aimed to find MMT peritoneum with EPS.
These findings represent important evidence linking both
processes, but indirect evidence may also be marked. In
human studies [10] and in experimental animals (unpub-
lished data), our studies demonstrated a direct relationship
between MMT and time on PD. Similarly, the several studies
showed a parallel between EPS and time on PD [52, 53].
Another important fact is that peritoneal function studies
also show a parallel between high frequency ofMMTofMCs,
high Cr-MTC, and low ultrafiltration. Indeed we observed a
higher frequency of mesothelial fibroblastoid phenotype in
patients with type Cr-MTC >11mL/min [54]. Furthermore,
as is well known, patients with EPS even displayed these with
SPS showed similar functional PM deterioration [9, 55, 56].
Another indirect association between these two events is
peritonitis. Ya´n˜ez-Mo and coworkers [10] found that the
frequency of nonepithelioidMCwas associatedwith episodes
of peritonitis, thismeans that peritonitis leads to theMMT. In
the case of the EPS, there are some studies in the literature that
correlate it with peritonitis events. Previous studies suggest
that peritonitis may predispose to EPS, especially if this is
caused by Staphylococcus aureus, fungi, and/or Pseudomonas
[9, 57]. There is also an association between persistent infec-
tions such as tuberculosis peritonitis and EPS [58]. Although
peritonitis and EPS are highly associated in several studies
it is also known that, especially in a long-term case, EPS
may occur without peritonitis. Moreover, patients that have
suffered from more events of peritonitis have a higher
incidence of MMT and EPS, which suggest again that these
processes are related. Finally, we have analyzed more than
10 peritoneal biopsies from patients with EPS where we had
found a significant amount of mesothelial cells (CK +) in the
peritoneal submesothelial area, which indicates that despite
the significant denudation of the peritoneal MCs monolayer
Figure 2: Evidence of MMT in EPS. Light microscopy analysis of
a parietal peritoneal biopsy from a patient with EPS. Despite sig-
nificant denudation of the peritoneal membrane, a submesothelial
cytokeratin staining (brown) in submesothelial area is observed.
This cytokeratin staining suggests the superficial precedence of these
cells (arrows). Magnification ×200.
persists and important migration of MCs to compact zone
(Figure 2).
3. Conclusion
TGF-𝛽 appears to be the most important molecule in the
initiation of MMT and peritoneal fibrosis. MMT is present
fromearly stages of peritoneal fibrosis and is perpetuated over
time. Current data support a connection between MMT and
SPS. However, the jump from SPS to EPS and the connection
between MMT and EPS have not been fully established. We
concluded that the MMT can be a therapeutic target, the
blockade ofwhich could be a benefit especially in initial stages
of the process.
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